| 17.12.2009 |
|
Financing round for Ophthotech |
| 11.12.2009 |
|
Successful IPO for China Nuokang |
| 20.11.2009 |
|
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA |
| 30.10.2009 |
|
HBM BioVentures Quarterly Report as at 30 September 2009 |
| 08.10.2009 |
|
Paratek Pharmaceuticals, a portfolio company of HBM BioVentures, signs licence agreement over USD 485 million |
| 02.10.2009 |
|
Closing of the successful sale of BRAHMS to Thermo Fisher Scientific |
| 14.09.2009 |
|
Successful sale of ESBATech, a Swiss company from HBM BioVentures' portfolio, to Alcon leads to immediate NAV increase of CHF 1.75 and cash inflow of CHF 18.6 million |
| 04.09.2009 |
|
HBM BioVentures Ordinary Shareholders' Meeting
All Board of Directors' proposals approved with clear majority |
| 03.09.2009 |
|
Successful sale of BRAHMS in an all cash transaction to Therma Fisher Scientific leads to NAV increase of CHF 8,88, or 15,5% |
| 26.08.2009 |
|
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA |
| 11.08.2009 |
|
HBM BioVentures: Agenda for the Shareholders' Meeting |
| 11.08.2009 |
|
HBM BioVentures: Invitation to the 8th Ordinary Shareholders' Meeting |
| 30.07.2009 |
|
HBM BioVentures Quarterly Report as at 30 June 2009 |
| 08.07.2009 |
|
HBM BioVentures reduces its outstanding Going Public Convertible Bond by CHF 39 million |
| 03.06.2009 |
|
HBM BioVentures Annual Report 2008/2009 |
| 11.05.2009 |
|
HBM BioVentures: letter to shareholders |
| 02.04.2009 |
|
HBM BioVentures net asset value as at 31 March 2009 |
| 30.01.2009 |
|
HBM BioVentures quarterly report as at 31 December 2008 |
